Serum Procalcitonin for Differentiating Bacterial Infection from Disease Flares in Patients with Autoimmune Diseases by Joo, Kowoon et al.
© 2011 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Serum Procalcitonin for Differentiating Bacterial Infection from 
Disease Flares in Patients with Autoimmune Diseases
Early differentiation between bacterial infections and disease flares in autoimmune disease 
patients is important due to different treatments. Seventy-nine autoimmune disease 
patients with symptoms suggestive of infections or disease flares were collected by 
retrospective chart review. The patients were later classified into two groups, disease flare 
and infection. C-reactive protein (CRP) and serum procalcitonin (PCT) levels were 
measured. The CRP and PCT levels were higher in the infection group than the disease flare 
group (CRP,11.96 mg/dL ± 9.60 vs 6.42 mg/dL ± 7.01, P = 0.003; PCT, 2.44 ng/mL ± 6.55 
vs 0.09 ng/mL ± 0.09, P < 0.001). The area under the ROC curve (AUC; 95% confidence 
interval) for CRP and PCT was 0.70 (0.58-0.82) and 0.84 (0.75-0.93), which showed a 
significant difference (P < 0.05). The predicted AUC for the CRP and PCT levels combined 
was 0.83, which was not significantly different compared to the PCT level alone (P = 0.80). 
The best cut-off value for CRP was 7.18 mg/dL, with a sensitivity of 71.9% and a 
specificity of 68.1%. The best cut-off value for PCT was 0.09 ng/mL, with a sensitivity of 
81.3% and a specificity of 78.7%. The PCT level had better sensitivity and specificity 
compared to the CRP level in distinguishing between bacterial infections and disease flares 
in autoimmune disease patients. The CRP level has no additive value when combined with 
the PCT level when differentiating bacterial infections from disease flares.
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INTRODUCTION
Early differentiation between bacterial infections and disease 
flares in patients with autoimmune disease is important due to 
different treatment modalities. Unfortunately, discriminating 
between bacterial infections and disease flares in patients with 
underlying autoimmune diseases is difficult because of the sim-
ilar clinical presentations and laboratory findings. The white 
blood cell (WBC) count, erythrocyte sedimentation rate (ESR), 
and C-reactive protein (CRP) level are not always helpful in dis-
tinguishing between bacterial infections and disease flares in 
patients with autoimmune diseases because these markers are 
elevated not only in infectious conditions, but also when the un-
derlying disease flares (1). Moreover, inflammatory signs can be 
masked and the CRP level decreased with corticosteroid thera-
py or immunosuppression (2), which are basic treatments for 
autoimmune disease, rendering CRP inconsistently reliable as 
a biomarker for bacterial infection in these patient groups.
  Recently, several studies have focused on new markers to dis-
tinguish between bacterial infections and disease flares in pa-
tients with autoimmune diseases. Procalcitonin (PCT) is one 
such marker, for which a number of clinical studies have been 
published. PCT is a protein with a molecular weight of 13 kDa 
that is produced by the C cells of the thyroid gland as a precursor 
protein of calcitonin (3). The origin of the synthesis and secre-
tion of PCT during infections are considered to be extra-thyroi-
dal because it has been possible to demonstrate its production 
in the lung, liver, pancreas, colon, and other organs (4, 5). PCT 
behaves like an acute phase protein (6) similar to other positive 
reactants, such as CRP, the production of which is also increased 
by inflammatory stimuli, including infections (7). After a bacte-
rial stimulus in healthy volunteers, the PCT level rise within 4 hr, 
reaching peak levels after 6 hours, and maintaining a plateau 
between 8 and 24 hr (8). Serum PCT is normally undetectable 
(< 0.05 ng/mL) and PCT levels > 0.5 ng/mL are used to distin-
guish infections from non-infectious inflammation (9, 10). Most 
of the published observational studies on PCT in autoimmune 
diseases have used a semi-quantitative test for PCT measure-
ment (functional assay sensitivity, < 0.5 ng/mL). 
  The object of this study was to determine the usefulness of 
serum PCT levels in patients with underlying autoimmune dis-
ease. We compared the PCT level in groups with autoimmune 
disease flares and groups with autoimmune disease complicat-
ed by infectious diseases. A highly sensitive PCT immunoassay 
with a functional assay sensitivity of 0.09 ng/mL (11) was used.Joo K, et al.  •  Procalcitonin in Autoimmune Diseases
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MATERIALS AND METHODS
Subjects 
The serum PCT and CRP levels were measured in 79 patients 
(23 males and 56 females) with underlying autoimmune disease 
(adult-onset Still’s disease [AOSD], n = 3; ankylosing spondylitis 
[AS], n = 9; Behcet’s disease [BD], n = 8; microscopic polyangitis 
[MPA], n = 1; polyarteritis nodosa [PAN], n = 1; rheumatoid ar-
thritis [RA], n = 33; Sjogren’s disease [SD], n = 2; systemic lupus 
erythematosus [SLE], n = 16; systemic sclerosis [SSc], n = 5; We-
gener’s granulomatosis [WG], n = 1) who were admitted to the 
university hospital between September 2009 and September 
2010. 
Measurements
The patients were retrospectively classified into 2 groups (dis-
ease flares and infections). Serum PCT and CRP levels were mea-
sured using an enzyme-linked fluorescent assay (bioMerieux 
Co., Marcy L’Etoile, France) and a turbidimetric immunoassay 
(Hitachi High-Technologies Corp., Tokyo, Japan).
  Infections were diagnosed in 32 patients. The diagnosis of a 
bacterial infection was made based on the presence of a posi-
tive pathogen test from various specimens (blood, sputum, pus, 
and urine), clear evidence of infection (pneumonic infiltration 
on computed tomography [CT]), and clear clinical signs corre-
lating with infection. The infection group was further classified 
into two subgroups (systemic inflammatory response syndrome 
[SIRS] and non-SIRS), following the criteria described by Bone 
et al. (12). SIRS was diagnosed when 2 or more of the following 
conditions were observed: 1) temperature > 38°C or < 36°C; 2) 
heart rate > 90 beats per minute; 3) respiratory rate > 20 breaths 
per minute or PaO2 < 32 mmHg; and 4) white blood cell count  
> 12,000/μL, < 4,000/μL, or > 10% immature (band) forms. 
  Disease flare was diagnosed in 47 patients. The diagnosis of  
a disease flare was made when there was a significant increase 
in the activity score based on the following disease activity index 
compared to the previous condition which was not caused by 
any other conditions, such as infection or drug use, and when 
hospitalization was clinically needed for further treatment. The 
disease activity index used in each disease was as follows; DAS-
28CRP (Disease Activity Score; 13) in RA patients; Systemic Lu-
pus Erythematosus Disease Activity Index (SLEDAI; 14) in SLE 
patients; highly increased ferritin level in AOSD patients (15); Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI) (16) in 
AS patients; Behcet’s Disease Current Activity Form (BDCAF) 
(17) in Behcet’s disease patients; European League Against Rheu-
matism Sjogren’s Syndrome Disease Activity Index (ESSDAI) (18) 
in Sjogren’s disease patients; Valentini Scleroderma Disease Ac-
tivity Index (SDAI) (19) in SSc patients; and Birmingham Vascu-
litis Disease Activity Score (BVDAS) (20) in vasculitis patients. 
  There were no cases in this study in which an infection and 
disease flare were suspected at the same time. This study was 
conducted retrospectively and diagnostically-ambiguous cases 
were excluded. 
Statistical analysis
Statistical analysis was carried out using the Statistical Package 
for the Social Sciences (version 18.0; SPSS, Inc., Chicago, IL, USA). 
For comparing the two samples, the Mann-Whitney U test was 
used. An estimated receiver operating characteristic (ROC) curve 
was used to evaluate the diagnostic power of the CRP and PCT 
levels by determining the area under the curve (AUC). The sen-
sitivity and specificity of the estimated best cut-off values were 
also calculated from the ROC curve. A value of P < 0.05 was con-
sidered significant.
Ethics statement
This study was approved by the institutional review board of Inha 
University Hospital (IRB No. 11-0478). The board exempted in-
formed consent because it was a retrospective study.
RESULTS
Among the 79 patients reviewed, 47 were identified with disease 
flares and 32 were identified with bacterial infections. Thirty-four 
patients had fever (disease flare [n = 11] and infection [n = 23]) 
and 20 patients satisfied the criteria for SIRS (disease flare [n = 
9] and infection [n = 11]). The mean ages for disease flares and 
bacterial infections were 47 ± 17 yr and 59 ± 16 yr, respectively 
Table 1. The demographic and laboratory findings for the disease flare and infection 
groups
Characteristics Disease flare Infection
Number of cases 47 32
Age (yr)
   Mean
  
47
  
59
Gender
   Male
   Female
 
15
32
 
  8
24
Fever
   No
   Yes
 
36
11
 
  9
23
SIRS
   No
   Yes
 
38
  9 
 
21
11
CRP (mg/dL)
   Mean ± SD
   Median
   Minimum
   Maximum
 
6.42 ± 7.01
  4.42
  0.04
27.04
 
11.96 ± 9.6
      9.305
    0.07
35.1
PCT (ng/mL)
   Mean ± SD
   Median
   Minimum
   Maximum
 
0.09 ± 0.09
  0.05
  0.05
  0.41
 
2.44 ± 6.55
   0.25
   0.05
 29.73
SIRS, Systemic inflammatory response syndrome; CRP, C-reactive protein; PCT, pro-
calcitonin; SD, standard deviation.Joo K, et al.  •  Procalcitonin in Autoimmune Diseases
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(Table 1). 
  In the bacterial infection group, bacteria were identified in 14 
of 32 cases. Nine cases had pneumonic infiltration on chest CT 
and 9 cases had clinical signs correlated with infection.
  The odds ratio (OR) for fever in the differentiation of bacterial 
infections from disease flares was 8.36 (95% confidence interval 
[CI], 3.00-23.39), which was superior to SIRS (OR, 2.21; 95% CI, 
0.79-6.19). 
  The CRP and PCT levels were higher in the infection group 
than the disease flare group (CRP, 11.96 ± 9.60 mg/dL vs 6.42 ± 
7.01 mg/dL, P = 0.003; PCT, 2.44 ± 6.55 ng/mL vs 0.09 ± 0.09 ng/
mL, P < 0.001; Figs. 1, 2). 
  The area under the ROC curves (AUC; 95% CI) for CRP and 
PCT was 0.70 (0.58-0.82) and 0.84 (0.75-0.93), respectively, which 
was a significant difference (P < 0.05). The predicted AUC for 
CRP and PCT combined was 0.83, which was not significantly 
different compared to PCT alone (P = 0.80). The best cutoff value 
for CRP was 7.18 mg/dL, with a sensitivity of 71.9% and a speci-
ficity of 68.1%. The best cut-off value for PCT was 0.09 ng/mL, 
with a sensitivity of 81.3% and a specificity of 78.7% (Fig. 3).
DISCUSSION
Identifying bacterial infections and disease flares in patients with 
autoimmune diseases is important because the treatment mo-
dalities for each condition differ. The immediate use of antibiot-
ics is needed in the bacterial infection group while immunosup-
pressive drugs are needed in the disease flare group. The wrong 
choice between the two treatment modalities may aggravate the 
patient’s condition and sometimes the results are fatal. This study 
showed the CRP and PCT levels to be significantly higher in the 
infection group than in the autoimmune disease flare group.
  Most of the published observational studies on PCT in pa-
tients with autoimmune diseases have used a semi-quantitative 
test for PCT measurement (functional assay sensitivity, 0.5 ng/
mL). The normal serum procalcitonin level is < 0.05 ng/mL and 
because 0.5 ng/mL exceeds the average normal value by > 10-
fold, many mild increases in PCT were missed. Therefore, most 
studies published that the serum PCT level > 0.5 ng/mL is use-
ful in distinguishing infectious from non-infectious inflamma-
tion (9, 10), and some studies (2) have used PCT levels to distin-
guish sepsis from disease flares. In the current study we used an 
enzyme-linked fluorescent assay (bioMerieux Co.) with a func-
tional sensitivity of 0.09 ng/mL, which made levels < 0.5 ng/mL 
detectable with accuracy. This functional sensitivity enabled not 
only sepsis, but also localized bacterial infection to be accurate-
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Fig. 1. Box-plot diagram for CRP in disease flare and infection groups, with box en-
compassing the range of levels from the 25th percentile (lower bar) to the 75th per-
centile (upper bar). The horizontal line within the box indicates the median value. The 
extreme values (within 1.5 times the inter-quartile range [IQR] from the upper or lower 
quartile) are the ends of the lines extending from the IQR.
Group
P
C
T
 
(
n
g
/
d
L
)
  Disease flare  Infection
1.50
1.00
0.50
0.00
Fig. 2. Boxplot for procalcitonin (PCT) in disease flare and infection groups. The ex-
planation is the same as in Fig. 1. 
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Fig. 3. Receiver operating characteristics (ROC) curve for CRP and PCT levels in differ-
entiating bacterial infections from disease flares. The area under the curve (AUC) was 
0.70 (95% CI, 0.58-0.82) for CRP and 0.84 (95% CI, 0.75-0.93) for PCT. Predicted 
AUC for CRP and PCT combined was 0.83.
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ly differentiated from disease flares. 
  Lanoix et al. (21) reported that the serum PCT level is not dif-
ferent between infections and disease flares in patients with SLE. 
Specifically, Lanoix et al. used an automated immunofluoromet-
ric assay (Brahms Co., Berlin, Germany) to measure PCT levels, 
which considered PCT levels < 0.5 ng/mL to be normal. Five peo-
ple were categorized in the infection group (which is a limitation 
of that study) and the PCT was normal in the all 5 patients using 
the above standard. In the current study we used a more refined 
assay method to define serum PCT levels and the normal value 
was < 0.05 ng/mL. In the current study 4 of 5 SLE patients in the 
infection group had elevated PCT levels (> 0.09 ng/mL). 
  Two AOSD patients and one Wegener’s granulomatosis pa-
tient in the disease flare group had high serum PCT levels with-
out infections. It has been reported that serum PCT levels are 
higher in patients with active antineutrophil cytoplasmic anti-
body-associated vasculitis and in patients with AOSD (22, 23). 
Different PCT levels can be expected in different autoimmune 
diseases. However, the optimal cut-off values for PCT in differ-
ent patient groups with different autoimmune diseases have not 
been established.
  The OR for fever in distinguishing bacterial infections from 
disease flares is superior compared to SIRS. The probable rea-
son for this is the fact that most of the patients in this study had 
localized infections and there were only two patients with posi-
tive bacterial blood cultures. 
  One patient with a positive bacterial blood culture had a high 
PCT level (29.7 ng/mL). Higher PCT levels can be expected in 
sepsis compared to localized bacterial infections (24), but there 
were not a sufficient number of sepsis patients to accurately cal-
culate the optical cut-off value for sepsis.
  Previous studies have reported the diagnostic accuracy of se-
rum PCT for bacterial infections, but the sensitivity and specific-
ity were variable. In the current study the PCT level had better 
sensitivity and specificity compared to the CRP level (81.3% vs 
71.9% and 78.7% vs 68.1%, respectively). A meta-analysis report-
ed a serum PCT sensitivity range from 42%-100% and a speci-
ficity range from 54%-100%, while a CRP sensitivity range from 
35%-100% and a specificity range from 18%-82% (25). There are 
no meta-analyses involving serum PCT levels in differentiating 
bacterial infections from disease flares in patients with autoim-
mune diseases.
  The best cut-off value for CRP in differentiating infections from 
autoimmune disease flares was 7.18 mg/dL. This value varies 
with different autoimmune diseases, but is similar to the study 
by Pepys et al. (26) which reported that a marked CRP elevation 
(> 6 or 7 mg/dL) in febrile lupus patients favors the diagnosis of 
bacterial infections.
  The predicted AUC for CRP and PCT combined was 0.83, 
which was not significantly different compared to PCT alone. 
The CRP level had no additive value when combined with the 
PCT level in differentiating bacterial infections from autoim-
mune disease flares. Indeed, this is the first study in which the 
combined AUC for CRP and PCT was analyzed. 
  This study showed that serum PCT is useful for differentiating 
bacterial infections from disease flares in patients with autoim-
mune disease. It should be clear that no single biomarker is suf-
ficiently sensitive or specific to be relied on completely, and PCT 
alone cannot replace a physical examination or a thorough med-
ical history. A more accurate analysis can be expected in future 
studies with a larger number of patients and with each different 
autoimmune disease group analyzed separately.
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